From: Duration of diaphragmatic inactivity after endotracheal intubation of critically ill patients
Characteristic | Study population (n = 69) |
---|---|
Male, n (%) | 41 (59.42) |
Age (years), mean ± SD | 63.33 ± 16.58 |
Body mass index, (kg/m2), mean ± SD | 28.68 ± 9.31 |
Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II Scoring System (score) | |
 Mean ± SD | 24.62 ± 8.28 |
 Median (IQR) | 24.50 [19.00–30.00] |
Reason for ICU admission, n (%) | |
 Elective surgery | 1 (1.45) |
 Emergency surgery | 5 (7.25) |
 Trauma | 5 (7.25) |
 Medical | 58 (84.06) |
Reason for intubation, n (%) | |
 Pulmonary | 38 (55.07) |
 Hemodynamic | 13 (18.84) |
 Neurologic | 14 (20.29) |
 Airway protection | 4 (5.80) |
Intubation time, n (%) | |
 Day (6am–9 pm) | 57 (82.61) |
 Night (9 pm–6am) | 12 (17.39) |
Arterial blood gasa | |
 FiO2, median (IQR) | 0.50 [0.50–0.70] |
 PaO2 (mmHg), mean ± SD | 121.84 ± 48.86 |
 PaCO2 (mmHg), mean ± SD | 44.16 ± 10.89 |
 HCO3 (mmol/L), mean ± SD | 23.58 ± 6.24 |
 PaO2/FiO2 (mmHg), mean ± SD | 226.36 ± 104.82 |
Baseline creatinine (µmol/L), median [IQR] | 106.00 [71.00–176.00] |
Baseline acute kidney injury stage, n (%)f | |
 No acute kidney injury | 33 (47.83) |
 1 | 22 (31.88) |
 2 | 4 (5.80) |
 3 | 10 (14.49) |
Baseline bilirubin (µmol/L)c, median [IQR] | 10.00 [7.00–17.00] |
Ventilatory settings at diaphragm electrical activity catheter connection | |
 Volume or pressure assist-control ventilation, n (%) | 62 (89.86) |
PEEP (cmH2O), mean ± SD | |
 All patients | 8.05 ± 2.96 |
 Patients on controlled mode (n = 62) | 8.08 ± 3.08 |
 Patients on assisted mode (n = 7) | 7.83 ± 1.72 |
Mean airway pressure (cmH2O), mean ± SD | |
 All patients | 12.50 ± 3.93 |
 Patients on controlled mode (n = 62) | 12.73 ± 4.01 |
 Patients on assisted mode (n = 7) | 10.54 ± 2.53 |
Time with available diaphragm electrical activity recording (hours), median (IQR) | 69.20 [45.05–96.20] |
Tracheostomy during ICU stay, n (%)b | 7 (10.14) |
Mortality, n (%) | |
 At ICU discharge | 17 (24.64) |
 At hospital dischargec | 25 (36.76) |
Resumption of diaphragm electrical activity during study periodd | |
 Subjects with complete recordings, n (%) | 61 (88.41) |
 Time to resumption, n (%) | |
  < 24 h | 35 (57.38) |
  24 h–48 h | 11 (18.03) |
  48 h–72 h | 6 (9.84) |
  72 h–96 h | 5 (8.20) |
  > 96 h (no resumption) | 4 (6.56) |
 Estimated time (hours) to resumptione | |
  Median (IQR) | 22.02 [0.00–50.28] |
  Mean ± SE | 35.20 ± 4.93 |
 Average diaphragm electrical activity (µV) during resumption, mean ± SD | 8.60 ± 7.07 |
Use of sedative during the first 24Â h, n (%)g | 63 (91.30) |
 Propofol, n (%) | 49 (77.78) |
  Cumulative dose (mg/kg), median [IQR] | 18.99 [9.60–32.86] |
 Midazolam, n (%) | 46 (73.02) |
  Cumulative dose (mg/kg), median [IQR] | 0.07 [0.03–0.59] |
 Fentanyl, n (%) | 51 (80.95) |
  Cumulative dose (µg/kg), median [IQR] | 4.40 [1.40–15.91] |
Neuromuscular blocking agent use, n (%)h | |
 No | 16 (23.19) |
 Yes | 53 (76.81) |
 Yes, for intubation | 49 (71.01) |
 Yes, additional bolus or continuous infusion | 4 (5.80) |
Sedation analgesia score (during the first 6Â h of diaphragm electrical activity recording)i | |
 Median (IQR) | 1.75 [1.00–2.50] |